Preclinical characterisation of the protective capacity of an anti-nucleoprotein hRSV monoclonal antibody.

ABSTRACT:

Background

The human respiratory syncytial virus (hRSV) is a pathogen of global concern, causing significant morbidity and mortality, mainly in preterm infants. To date, all licenced monoclonal antibodies (mAbs) developed against hRSV have targeted its surface fusion or pre-fusion protein (F-hRSV).

Methods

We developed mAbs against the hRSV nucleoprotein (N-hRSV) as a complementary prophylactic treatment. Firstly, we produced a humanised murine mAb against N-hRSV, yielding four clones. Antibody affinity assays against the N-hRSV protein, pharmacokinetic analyses, and protection assays against pulmonary and neurological pathologies associated with hRSV infection in an in vivo male and female BALB/c murine model were performed. In vitro assays were carried out to determine the

SUBMITTER: Farias MA 

PROVIDER: S-EPMC12805088 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature